#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=2 .
1-1	0-1	2	quantity	new	_	_
1-2	2-3	.	_	_	_	_

#Text=Conventional Mouse Models for Liver Cancer
2-1	4-16	Conventional	abstract[2]	new[2]	coref	3-6[6_2]
2-2	17-22	Mouse	abstract[2]	new[2]	_	_
2-3	23-29	Models	abstract[2]	new[2]	_	_
2-4	30-33	for	abstract[2]	new[2]	_	_
2-5	34-39	Liver	abstract[2]|place|abstract[4]	new[2]|new|new[4]	coref|coref|coref|coref	5-12|5-12[20_4]|5-12|5-12[20_4]
2-6	40-46	Cancer	abstract[2]|abstract[4]	new[2]|new[4]	_	_

#Text=A relatively large number of mouse models are presently available for the study of hepatocarcinogenesis .
3-1	47-48	A	abstract[5]	new[5]	_	_
3-2	49-59	relatively	abstract[5]	new[5]	_	_
3-3	60-65	large	abstract[5]	new[5]	_	_
3-4	66-72	number	abstract[5]	new[5]	_	_
3-5	73-75	of	abstract[5]	new[5]	_	_
3-6	76-81	mouse	abstract[5]|abstract[6]	new[5]|giv[6]	_	_
3-7	82-88	models	abstract[5]|abstract[6]	new[5]|giv[6]	_	_
3-8	89-92	are	_	_	_	_
3-9	93-102	presently	_	_	_	_
3-10	103-112	available	_	_	_	_
3-11	113-116	for	_	_	_	_
3-12	117-120	the	abstract[7]	new[7]	coref	16-11[80_7]
3-13	121-126	study	abstract[7]	new[7]	_	_
3-14	127-129	of	abstract[7]	new[7]	_	_
3-15	130-150	hepatocarcinogenesis	abstract[7]|abstract	new[7]|new	coref	10-1[30_0]
3-16	151-152	.	_	_	_	_

#Text=The common ones are chemically induced models , genetically engineered mouse ( GEM ) models , implantation models , and viral models .
4-1	153-156	The	abstract[9]	new[9]	coref	4-5[10_9]
4-2	157-163	common	abstract[9]	new[9]	_	_
4-3	164-168	ones	abstract[9]	new[9]	_	_
4-4	169-172	are	_	_	_	_
4-5	173-183	chemically	abstract[10]	giv[10]	appos	4-15[13_10]
4-6	184-191	induced	abstract[10]	giv[10]	_	_
4-7	192-198	models	abstract[10]	giv[10]	_	_
4-8	199-200	,	_	_	_	_
4-9	201-212	genetically	animal[11]	new[11]	coref	5-9[0_11]
4-10	213-223	engineered	animal[11]	new[11]	_	_
4-11	224-229	mouse	animal[11]	new[11]	_	_
4-12	230-231	(	_	_	_	_
4-13	232-235	GEM	substance	new	coref	34-5
4-14	236-237	)	_	_	_	_
4-15	238-244	models	abstract[13]	giv[13]	coref	5-8[18_13]
4-16	245-246	,	abstract[13]	giv[13]	_	_
4-17	247-259	implantation	abstract[13]|abstract	giv[13]|new	_	_
4-18	260-266	models	abstract[13]	giv[13]	_	_
4-19	267-268	,	abstract[13]	giv[13]	_	_
4-20	269-272	and	abstract[13]	giv[13]	_	_
4-21	273-278	viral	abstract[13]	giv[13]	_	_
4-22	279-285	models	abstract[13]	giv[13]	_	_
4-23	286-287	.	_	_	_	_

#Text=Our aim here is not to review all mouse models for liver cancer but rather to provide examples of the representative ones , mostly chemically induced or genetically engineered models ( GEMs ) that have been integrated to genomics of human HCCs (
5-1	288-291	Our	person|abstract[16]	acc|new[16]	_	_
5-2	292-295	aim	abstract[16]	new[16]	_	_
5-3	296-300	here	_	_	_	_
5-4	301-303	is	_	_	_	_
5-5	304-307	not	_	_	_	_
5-6	308-310	to	_	_	_	_
5-7	311-317	review	_	_	_	_
5-8	318-321	all	abstract[18]	giv[18]	coref	5-20[22_18]
5-9	322-327	mouse	animal|abstract[18]	giv|giv[18]	coref	14-4[59_0]
5-10	328-334	models	abstract[18]	giv[18]	_	_
5-11	335-338	for	abstract[18]	giv[18]	_	_
5-12	339-344	liver	abstract[18]|object|abstract[20]	giv[18]|giv|giv[20]	coref|coref|coref|coref	11-8|11-8[36_20]|11-8|11-8[36_20]
5-13	345-351	cancer	abstract[18]|abstract[20]	giv[18]|giv[20]	_	_
5-14	352-355	but	_	_	_	_
5-15	356-362	rather	_	_	_	_
5-16	363-365	to	_	_	_	_
5-17	366-373	provide	_	_	_	_
5-18	374-382	examples	abstract[21]	new[21]	_	_
5-19	383-385	of	abstract[21]	new[21]	_	_
5-20	386-389	the	abstract[21]|abstract[22]	new[21]|giv[22]	coref	5-24[23_22]
5-21	390-404	representative	abstract[21]|abstract[22]	new[21]|giv[22]	_	_
5-22	405-409	ones	abstract[21]|abstract[22]	new[21]|giv[22]	_	_
5-23	410-411	,	abstract[21]	new[21]	_	_
5-24	412-418	mostly	abstract[21]|abstract[23]	new[21]|giv[23]	coref	9-1[29_23]
5-25	419-429	chemically	abstract[21]|abstract[23]	new[21]|giv[23]	_	_
5-26	430-437	induced	abstract[21]|abstract[23]	new[21]|giv[23]	_	_
5-27	438-440	or	abstract[21]|abstract[23]	new[21]|giv[23]	_	_
5-28	441-452	genetically	abstract[21]|abstract[23]	new[21]|giv[23]	_	_
5-29	453-463	engineered	abstract[21]|abstract[23]	new[21]|giv[23]	_	_
5-30	464-470	models	abstract[21]|abstract[23]	new[21]|giv[23]	_	_
5-31	471-472	(	_	_	_	_
5-32	473-477	GEMs	object	new	_	_
5-33	478-479	)	_	_	_	_
5-34	480-484	that	_	_	_	_
5-35	485-489	have	_	_	_	_
5-36	490-494	been	_	_	_	_
5-37	495-505	integrated	_	_	_	_
5-38	506-508	to	_	_	_	_
5-39	509-517	genomics	abstract[25]	new[25]	_	_
5-40	518-520	of	abstract[25]	new[25]	_	_
5-41	521-526	human	abstract[25]|object[26]	new[25]|new[26]	coref	37-42[264_26]
5-42	527-531	HCCs	abstract[25]|object[26]	new[25]|new[26]	_	_
5-43	532-533	(	_	_	_	_

#Text=Figure 1
6-1	534-540	Figure	object[27]	new[27]	_	_
6-2	541-542	1	object[27]	new[27]	_	_

#Text=) .
7-1	543-544	)	_	_	_	_
7-2	545-546	.	_	_	_	_

#Text=2.1 .
8-1	547-550	2.1	abstract	new	_	_
8-2	551-552	.	_	_	_	_

#Text=Chemically Induced Models
9-1	553-563	Chemically	abstract[29]	giv[29]	_	_
9-2	564-571	Induced	abstract[29]	giv[29]	_	_
9-3	572-578	Models	abstract[29]	giv[29]	_	_

#Text=Chemically induced hepatocarcinogenesis is caused by an irreversible process of structural DNA changes .
10-1	579-589	Chemically	abstract[30]	giv[30]	coref	15-22[0_30]
10-2	590-597	induced	abstract[30]	giv[30]	_	_
10-3	598-618	hepatocarcinogenesis	abstract[30]	giv[30]	_	_
10-4	619-621	is	_	_	_	_
10-5	622-628	caused	_	_	_	_
10-6	629-631	by	_	_	_	_
10-7	632-634	an	abstract[31]	new[31]	_	_
10-8	635-647	irreversible	abstract[31]	new[31]	_	_
10-9	648-655	process	abstract[31]	new[31]	_	_
10-10	656-658	of	abstract[31]	new[31]	_	_
10-11	659-669	structural	abstract[31]|abstract[33]	new[31]|new[33]	coref	17-11[87_33]
10-12	670-673	DNA	abstract[31]|abstract|abstract[33]	new[31]|new|new[33]	coref	12-4
10-13	674-681	changes	abstract[31]|abstract[33]	new[31]|new[33]	_	_
10-14	682-683	.	_	_	_	_

#Text=The most widely used chemical to induce liver cancer in mice is diethylnitrosamine ( DEN ) ( Table 1 ) .
11-1	684-687	The	substance[34]	new[34]	coref	11-13[0_34]
11-2	688-692	most	substance[34]	new[34]	_	_
11-3	693-699	widely	substance[34]	new[34]	_	_
11-4	700-704	used	substance[34]	new[34]	_	_
11-5	705-713	chemical	substance[34]	new[34]	_	_
11-6	714-716	to	_	_	_	_
11-7	717-723	induce	_	_	_	_
11-8	724-729	liver	object|abstract[36]	giv|giv[36]	coref|coref	36-4[0_36]|36-4[0_36]
11-9	730-736	cancer	abstract[36]	giv[36]	_	_
11-10	737-739	in	_	_	_	_
11-11	740-744	mice	animal	new	coref	12-11[43_0]
11-12	745-747	is	_	_	_	_
11-13	748-766	diethylnitrosamine	substance	giv	coref	27-9
11-14	767-768	(	_	_	_	_
11-15	769-772	DEN	abstract	new	coref	12-1
11-16	773-774	)	_	_	_	_
11-17	775-776	(	_	_	_	_
11-18	777-782	Table	_	_	_	_
11-19	783-784	1	_	_	_	_
11-20	785-786	)	_	_	_	_
11-21	787-788	.	_	_	_	_

#Text=DEN is a DNA alkylating agent and when injected into juvenile mice , it forms mutagenic DNA adducts , which are generated rapidly in centrilobular hepatocytes .
12-1	789-792	DEN	substance	giv	ana	12-14
12-2	793-795	is	_	_	_	_
12-3	796-797	a	person[42]	new[42]	_	_
12-4	798-801	DNA	substance|person[42]	giv|new[42]	coref	12-17
12-5	802-812	alkylating	person[42]	new[42]	_	_
12-6	813-818	agent	person[42]	new[42]	_	_
12-7	819-822	and	_	_	_	_
12-8	823-827	when	_	_	_	_
12-9	828-836	injected	_	_	_	_
12-10	837-841	into	_	_	_	_
12-11	842-850	juvenile	animal[43]	giv[43]	coref	13-23[54_43]
12-12	851-855	mice	animal[43]	giv[43]	_	_
12-13	856-857	,	_	_	_	_
12-14	858-860	it	substance	giv	coref	13-1
12-15	861-866	forms	_	_	_	_
12-16	867-876	mutagenic	abstract[46]	new[46]	_	_
12-17	877-880	DNA	substance|abstract[46]	giv|new[46]	coref	15-26
12-18	881-888	adducts	abstract[46]	new[46]	_	_
12-19	889-890	,	_	_	_	_
12-20	891-896	which	_	_	_	_
12-21	897-900	are	_	_	_	_
12-22	901-910	generated	_	_	_	_
12-23	911-918	rapidly	_	_	_	_
12-24	919-921	in	_	_	_	_
12-25	922-935	centrilobular	object[47]	new[47]	coref	13-6[0_47]
12-26	936-947	hepatocytes	object[47]	new[47]	_	_
12-27	948-949	.	_	_	_	_

#Text=DEN is metabolic activated in hepatocytes by enzymes of the cytochrome P450 family and acts as a complete carcinogen if injected into young mice younger than two weeks old with actively proliferating hepatocytes resulting in dysplastic nodules , which progress to carcinoma .
13-1	950-953	DEN	substance	giv	coref	15-15
13-2	954-956	is	_	_	_	_
13-3	957-966	metabolic	person	new	_	_
13-4	967-976	activated	_	_	_	_
13-5	977-979	in	_	_	_	_
13-6	980-991	hepatocytes	object	giv	coref	13-33
13-7	992-994	by	_	_	_	_
13-8	995-1002	enzymes	abstract[51]	new[51]	_	_
13-9	1003-1005	of	abstract[51]	new[51]	_	_
13-10	1006-1009	the	abstract[51]|person[52]	new[51]|new[52]	_	_
13-11	1010-1020	cytochrome	abstract[51]|person[52]	new[51]|new[52]	_	_
13-12	1021-1025	P450	abstract[51]|person[52]	new[51]|new[52]	_	_
13-13	1026-1032	family	abstract[51]|person[52]	new[51]|new[52]	_	_
13-14	1033-1036	and	abstract[51]	new[51]	_	_
13-15	1037-1041	acts	abstract[51]|abstract	new[51]|new	_	_
13-16	1042-1044	as	abstract[51]	new[51]	_	_
13-17	1045-1046	a	abstract[51]	new[51]	_	_
13-18	1047-1055	complete	abstract[51]	new[51]	_	_
13-19	1056-1066	carcinogen	abstract[51]	new[51]	_	_
13-20	1067-1069	if	_	_	_	_
13-21	1070-1078	injected	_	_	_	_
13-22	1079-1083	into	_	_	_	_
13-23	1084-1089	young	animal[54]	giv[54]	coref	27-40[177_54]
13-24	1090-1094	mice	animal[54]	giv[54]	_	_
13-25	1095-1102	younger	animal[54]	giv[54]	_	_
13-26	1103-1107	than	_	_	_	_
13-27	1108-1111	two	time[55]	new[55]	_	_
13-28	1112-1117	weeks	time[55]	new[55]	_	_
13-29	1118-1121	old	_	_	_	_
13-30	1122-1126	with	_	_	_	_
13-31	1127-1135	actively	_	_	_	_
13-32	1136-1149	proliferating	_	_	_	_
13-33	1150-1161	hepatocytes	object	giv	_	_
13-34	1162-1171	resulting	_	_	_	_
13-35	1172-1174	in	_	_	_	_
13-36	1175-1185	dysplastic	object[57]	new[57]	_	_
13-37	1186-1193	nodules	object[57]	new[57]	_	_
13-38	1194-1195	,	_	_	_	_
13-39	1196-1201	which	_	_	_	_
13-40	1202-1210	progress	_	_	_	_
13-41	1211-1213	to	_	_	_	_
13-42	1214-1223	carcinoma	abstract	new	_	_
13-43	1224-1225	.	_	_	_	_

#Text=If given to an older mouse , additional stimulation is required for instance , phenobarbital ( PB ) , carbon tetrachloride , or high-fat diet feeding .
14-1	1226-1228	If	_	_	_	_
14-2	1229-1234	given	_	_	_	_
14-3	1235-1237	to	_	_	_	_
14-4	1238-1240	an	animal[59]	giv[59]	coref	21-15[0_59]
14-5	1241-1246	older	animal[59]	giv[59]	_	_
14-6	1247-1252	mouse	animal[59]	giv[59]	_	_
14-7	1253-1254	,	_	_	_	_
14-8	1255-1265	additional	abstract[60]	new[60]	_	_
14-9	1266-1277	stimulation	abstract[60]	new[60]	_	_
14-10	1278-1280	is	_	_	_	_
14-11	1281-1289	required	_	_	_	_
14-12	1290-1293	for	_	_	_	_
14-13	1294-1302	instance	_	_	_	_
14-14	1303-1304	,	_	_	_	_
14-15	1305-1318	phenobarbital	substance	new	_	_
14-16	1319-1320	(	_	_	_	_
14-17	1321-1323	PB	person	new	_	_
14-18	1324-1325	)	_	_	_	_
14-19	1326-1327	,	_	_	_	_
14-20	1328-1334	carbon	substance|substance[64]	new|new[64]	_	_
14-21	1335-1348	tetrachloride	substance[64]	new[64]	_	_
14-22	1349-1350	,	_	_	_	_
14-23	1351-1353	or	_	_	_	_
14-24	1354-1362	high-fat	event[65]	new[65]	coref	27-31[0_65]
14-25	1363-1367	diet	event[65]	new[65]	_	_
14-26	1368-1375	feeding	_	_	_	_
14-27	1376-1377	.	_	_	_	_

#Text=In addition , oxidative stress induced by reactive oxygen species ( ROS ) during DEN metabolization is known to contribute to hepatocarcinogenesis as they cause DNA , protein , and lipid damage .
15-1	1378-1380	In	_	_	_	_
15-2	1381-1389	addition	_	_	_	_
15-3	1390-1391	,	_	_	_	_
15-4	1392-1401	oxidative	abstract[66]	new[66]	_	_
15-5	1402-1408	stress	abstract[66]	new[66]	_	_
15-6	1409-1416	induced	_	_	_	_
15-7	1417-1419	by	_	_	_	_
15-8	1420-1428	reactive	abstract[68]	new[68]	_	_
15-9	1429-1435	oxygen	substance|abstract[68]	new|new[68]	_	_
15-10	1436-1443	species	abstract[68]	new[68]	_	_
15-11	1444-1445	(	_	_	_	_
15-12	1446-1449	ROS	substance	new	ana	15-24
15-13	1450-1451	)	_	_	_	_
15-14	1452-1458	during	_	_	_	_
15-15	1459-1462	DEN	substance|substance[71]	giv|new[71]	_	_
15-16	1463-1477	metabolization	substance[71]	new[71]	_	_
15-17	1478-1480	is	_	_	_	_
15-18	1481-1486	known	_	_	_	_
15-19	1487-1489	to	_	_	_	_
15-20	1490-1500	contribute	_	_	_	_
15-21	1501-1503	to	_	_	_	_
15-22	1504-1524	hepatocarcinogenesis	abstract	giv	coref	18-16
15-23	1525-1527	as	_	_	_	_
15-24	1528-1532	they	substance	giv	_	_
15-25	1533-1538	cause	_	_	_	_
15-26	1539-1542	DNA	substance	giv	coref	17-14
15-27	1543-1544	,	_	_	_	_
15-28	1545-1552	protein	substance	new	_	_
15-29	1553-1554	,	_	_	_	_
15-30	1555-1558	and	_	_	_	_
15-31	1559-1564	lipid	event|abstract[77]	new|new[77]	_	_
15-32	1565-1571	damage	abstract[77]	new[77]	_	_
15-33	1572-1573	.	_	_	_	_

#Text=The mutational landscape of a DEN-induced tumor was described in a recent study using the whole exome sequencing technique .
16-1	1574-1577	The	abstract[78]	new[78]	_	_
16-2	1578-1588	mutational	abstract[78]	new[78]	_	_
16-3	1589-1598	landscape	abstract[78]	new[78]	_	_
16-4	1599-1601	of	abstract[78]	new[78]	_	_
16-5	1602-1603	a	abstract[78]|abstract[79]	new[78]|new[79]	coref	35-22[0_79]
16-6	1604-1615	DEN-induced	abstract[78]|abstract[79]	new[78]|new[79]	_	_
16-7	1616-1621	tumor	abstract[78]|abstract[79]	new[78]|new[79]	_	_
16-8	1622-1625	was	_	_	_	_
16-9	1626-1635	described	_	_	_	_
16-10	1636-1638	in	_	_	_	_
16-11	1639-1640	a	abstract[80]	giv[80]	_	_
16-12	1641-1647	recent	abstract[80]	giv[80]	_	_
16-13	1648-1653	study	abstract[80]	giv[80]	_	_
16-14	1654-1659	using	_	_	_	_
16-15	1660-1663	the	abstract[83]	new[83]	_	_
16-16	1664-1669	whole	abstract[83]	new[83]	_	_
16-17	1670-1675	exome	abstract|abstract[83]	new|new[83]	_	_
16-18	1676-1686	sequencing	abstract|abstract[83]	new|new[83]	_	_
16-19	1687-1696	technique	abstract[83]	new[83]	_	_
16-20	1697-1698	.	_	_	_	_

#Text=A high burden of somatic mutation was observed and almost all of the DNA changes in the DEN-induced tumors were single-base substitutions . Four recurrently mutated genes that are putative oncogenic drivers of DEN-induced tumors were Hras , Braf , Egfr , and Apc .
17-1	1699-1700	A	abstract[84]	new[84]	_	_
17-2	1701-1705	high	abstract[84]	new[84]	_	_
17-3	1706-1712	burden	abstract[84]	new[84]	_	_
17-4	1713-1715	of	abstract[84]	new[84]	_	_
17-5	1716-1723	somatic	abstract[84]|abstract[85]	new[84]|new[85]	coref	23-2[130_85]
17-6	1724-1732	mutation	abstract[84]|abstract[85]	new[84]|new[85]	_	_
17-7	1733-1736	was	_	_	_	_
17-8	1737-1745	observed	_	_	_	_
17-9	1746-1749	and	_	_	_	_
17-10	1750-1756	almost	_	_	_	_
17-11	1757-1760	all	abstract[87]	giv[87]	coref	34-18[228_87]
17-12	1761-1763	of	abstract[87]	giv[87]	_	_
17-13	1764-1767	the	abstract[87]	giv[87]	_	_
17-14	1768-1771	DNA	substance|abstract[87]	giv|giv[87]	_	_
17-15	1772-1779	changes	abstract[87]	giv[87]	_	_
17-16	1780-1782	in	abstract[87]	giv[87]	_	_
17-17	1783-1786	the	abstract[87]|abstract[89]	giv[87]|new[89]	coref	17-34[94_89]
17-18	1787-1798	DEN-induced	abstract[87]|object|abstract[89]	giv[87]|new|new[89]	coref	17-34
17-19	1799-1805	tumors	abstract[87]|abstract[89]	giv[87]|new[89]	_	_
17-20	1806-1810	were	_	_	_	_
17-21	1811-1822	single-base	abstract[90]	new[90]	_	_
17-22	1823-1836	substitutions	abstract[90]	new[90]	_	_
17-23	1837-1838	.	_	_	_	_
17-24	1839-1843	Four	abstract[91]	new[91]	coref	22-8[125_91]
17-25	1844-1855	recurrently	abstract[91]	new[91]	_	_
17-26	1856-1863	mutated	abstract[91]	new[91]	_	_
17-27	1864-1869	genes	abstract[91]	new[91]	_	_
17-28	1870-1874	that	_	_	_	_
17-29	1875-1878	are	_	_	_	_
17-30	1879-1887	putative	_	_	_	_
17-31	1888-1897	oncogenic	person[92]	new[92]	coref	20-24[111_92]
17-32	1898-1905	drivers	person[92]	new[92]	_	_
17-33	1906-1908	of	person[92]	new[92]	_	_
17-34	1909-1920	DEN-induced	person[92]|object|abstract[94]	new[92]|giv|giv[94]	coref|coref|coref|coref	20-11|22-19[128_94]|20-11|22-19[128_94]
17-35	1921-1927	tumors	person[92]|abstract[94]	new[92]|giv[94]	_	_
17-36	1928-1932	were	_	_	_	_
17-37	1933-1937	Hras	abstract	new	coref	18-4
17-38	1938-1939	,	_	_	_	_
17-39	1940-1944	Braf	abstract	new	coref	20-2
17-40	1945-1946	,	_	_	_	_
17-41	1947-1951	Egfr	abstract	new	coref	20-5
17-42	1952-1953	,	_	_	_	_
17-43	1954-1957	and	_	_	_	_
17-44	1958-1961	Apc	abstract	new	coref	24-6
17-45	1962-1963	.	_	_	_	_

#Text=The incidence of Hras was the highest reaching approximately 80 % suggesting selective advantage during hepatocarcinogenesis .
18-1	1964-1967	The	abstract[99]	new[99]	_	_
18-2	1968-1977	incidence	abstract[99]	new[99]	_	_
18-3	1978-1980	of	abstract[99]	new[99]	_	_
18-4	1981-1985	Hras	abstract[99]|substance	new[99]|giv	coref	19-1
18-5	1986-1989	was	_	_	_	_
18-6	1990-1993	the	_	_	_	_
18-7	1994-2001	highest	_	_	_	_
18-8	2002-2010	reaching	_	_	_	_
18-9	2011-2024	approximately	quantity[101]	new[101]	_	_
18-10	2025-2027	80	quantity[101]	new[101]	_	_
18-11	2028-2029	%	quantity[101]	new[101]	_	_
18-12	2030-2040	suggesting	_	_	_	_
18-13	2041-2050	selective	abstract[102]	new[102]	_	_
18-14	2051-2060	advantage	abstract[102]	new[102]	_	_
18-15	2061-2067	during	_	_	_	_
18-16	2068-2088	hepatocarcinogenesis	abstract	giv	coref	34-13[225_0]
18-17	2089-2090	.	_	_	_	_

#Text=Hras
19-1	2091-2095	Hras	object	giv	_	_

#Text=, Braf , and Egfr mutations were present in every DEN-induced HCC with mutual exclusivity and may replace each other in terms of oncogenic drivers .
20-1	2096-2097	,	_	_	_	_
20-2	2098-2102	Braf	abstract	giv	_	_
20-3	2103-2104	,	_	_	_	_
20-4	2105-2108	and	_	_	_	_
20-5	2109-2113	Egfr	abstract|abstract[107]	giv|new[107]	coref|coref	36-26[250_107]|36-26[250_107]
20-6	2114-2123	mutations	abstract[107]	new[107]	_	_
20-7	2124-2128	were	_	_	_	_
20-8	2129-2136	present	_	_	_	_
20-9	2137-2139	in	_	_	_	_
20-10	2140-2145	every	object[109]	new[109]	coref	21-21[121_109]
20-11	2146-2157	DEN-induced	abstract|object[109]	giv|new[109]	coref	21-14
20-12	2158-2161	HCC	object[109]	new[109]	_	_
20-13	2162-2166	with	_	_	_	_
20-14	2167-2173	mutual	abstract[110]	new[110]	_	_
20-15	2174-2185	exclusivity	abstract[110]	new[110]	_	_
20-16	2186-2189	and	_	_	_	_
20-17	2190-2193	may	_	_	_	_
20-18	2194-2201	replace	_	_	_	_
20-19	2202-2206	each	_	_	_	_
20-20	2207-2212	other	_	_	_	_
20-21	2213-2215	in	_	_	_	_
20-22	2216-2221	terms	_	_	_	_
20-23	2222-2224	of	_	_	_	_
20-24	2225-2234	oncogenic	person[111]	giv[111]	_	_
20-25	2235-2242	drivers	person[111]	giv[111]	_	_
20-26	2243-2244	.	_	_	_	_

#Text=Activation of the Ras/Raf/MEK/ERK signal transduction pathway was the hallmark feature in the DEN-induced mouse model which is rare in human HCC .
21-1	2245-2255	Activation	abstract[112]	new[112]	coref	21-9[117_112]
21-2	2256-2258	of	abstract[112]	new[112]	_	_
21-3	2259-2262	the	abstract[112]|place[116]	new[112]|new[116]	coref	24-18[146_116]
21-4	2263-2278	Ras/Raf/MEK/ERK	abstract[112]|abstract|place[116]	new[112]|new|new[116]	_	_
21-5	2279-2285	signal	abstract[112]|abstract|place[116]	new[112]|new|new[116]	_	_
21-6	2286-2298	transduction	abstract[112]|abstract|place[116]	new[112]|new|new[116]	_	_
21-7	2299-2306	pathway	abstract[112]|place[116]	new[112]|new[116]	_	_
21-8	2307-2310	was	_	_	_	_
21-9	2311-2314	the	abstract[117]	giv[117]	_	_
21-10	2315-2323	hallmark	abstract[117]	giv[117]	_	_
21-11	2324-2331	feature	abstract[117]	giv[117]	_	_
21-12	2332-2334	in	abstract[117]	giv[117]	_	_
21-13	2335-2338	the	abstract[117]|abstract[120]	giv[117]|new[120]	coref	23-8[132_120]
21-14	2339-2350	DEN-induced	abstract[117]|abstract|abstract[120]	giv[117]|giv|new[120]	coref	22-19
21-15	2351-2356	mouse	abstract[117]|animal|abstract[120]	giv[117]|giv|new[120]	coref	34-1[221_0]
21-16	2357-2362	model	abstract[117]|abstract[120]	giv[117]|new[120]	_	_
21-17	2363-2368	which	_	_	_	_
21-18	2369-2371	is	_	_	_	_
21-19	2372-2376	rare	_	_	_	_
21-20	2377-2379	in	_	_	_	_
21-21	2380-2385	human	object[121]	giv[121]	coref	26-10[156_121]
21-22	2386-2389	HCC	object[121]	giv[121]	_	_
21-23	2390-2391	.	_	_	_	_

#Text=Of note , TP53 and CTNNB1 , the most frequently altered genes in human were never found in DEN-induced tumors .
22-1	2392-2394	Of	_	_	_	_
22-2	2395-2399	note	abstract	new	_	_
22-3	2400-2401	,	_	_	_	_
22-4	2402-2406	TP53	abstract	new	coref	30-9
22-5	2407-2410	and	_	_	_	_
22-6	2411-2417	CTNNB1	abstract	new	coref	23-2
22-7	2418-2419	,	_	_	_	_
22-8	2420-2423	the	abstract[125]	giv[125]	coref	29-28[201_125]
22-9	2424-2428	most	abstract[125]	giv[125]	_	_
22-10	2429-2439	frequently	abstract[125]	giv[125]	_	_
22-11	2440-2447	altered	abstract[125]	giv[125]	_	_
22-12	2448-2453	genes	abstract[125]	giv[125]	_	_
22-13	2454-2456	in	abstract[125]	giv[125]	_	_
22-14	2457-2462	human	abstract[125]|person	giv[125]|new	_	_
22-15	2463-2467	were	_	_	_	_
22-16	2468-2473	never	_	_	_	_
22-17	2474-2479	found	_	_	_	_
22-18	2480-2482	in	_	_	_	_
22-19	2483-2494	DEN-induced	object|abstract[128]	giv|giv[128]	coref|coref|coref|coref	23-8|30-19[209_128]|23-8|30-19[209_128]
22-20	2495-2501	tumors	abstract[128]	giv[128]	_	_
22-21	2502-2503	.	_	_	_	_

#Text=Although ctnnb1 mutation is not observed in DEN-induced model , its mutation is known to be observed in a two-stage model , the DEN-initiated and PB-promoted protocol .
23-1	2504-2512	Although	_	_	_	_
23-2	2513-2519	ctnnb1	abstract|abstract[130]	giv|giv[130]	coref|coref	23-11[134_130]|23-11[134_130]
23-3	2520-2528	mutation	abstract[130]	giv[130]	_	_
23-4	2529-2531	is	_	_	_	_
23-5	2532-2535	not	_	_	_	_
23-6	2536-2544	observed	_	_	_	_
23-7	2545-2547	in	_	_	_	_
23-8	2548-2559	DEN-induced	abstract|abstract[132]	giv|giv[132]	ana|ana	23-11[0_132]|23-11[0_132]
23-9	2560-2565	model	abstract[132]	giv[132]	_	_
23-10	2566-2567	,	_	_	_	_
23-11	2568-2571	its	abstract|abstract[134]	giv|giv[134]	coref|coref|coref|coref	23-19[135_0]|24-9[0_134]|23-19[135_0]|24-9[0_134]
23-12	2572-2580	mutation	abstract[134]	giv[134]	_	_
23-13	2581-2583	is	_	_	_	_
23-14	2584-2589	known	_	_	_	_
23-15	2590-2592	to	_	_	_	_
23-16	2593-2595	be	_	_	_	_
23-17	2596-2604	observed	_	_	_	_
23-18	2605-2607	in	_	_	_	_
23-19	2608-2609	a	abstract[135]	giv[135]	coref	25-1[148_135]
23-20	2610-2619	two-stage	abstract[135]	giv[135]	_	_
23-21	2620-2625	model	abstract[135]	giv[135]	_	_
23-22	2626-2627	,	_	_	_	_
23-23	2628-2631	the	abstract[138]	new[138]	_	_
23-24	2632-2645	DEN-initiated	abstract|abstract[138]	new|new[138]	_	_
23-25	2646-2649	and	abstract[138]	new[138]	_	_
23-26	2650-2661	PB-promoted	abstract|abstract[138]	new|new[138]	_	_
23-27	2662-2670	protocol	abstract[138]	new[138]	_	_
23-28	2671-2672	.	_	_	_	_

#Text=In addition , loss of Apc function , mutation and aberrant nuclear expression of β-catenin may disrupt the canonical Wnt/β-catenin pathway .
24-1	2673-2675	In	_	_	_	_
24-2	2676-2684	addition	_	_	_	_
24-3	2685-2686	,	_	_	_	_
24-4	2687-2691	loss	event[139]	new[139]	_	_
24-5	2692-2694	of	event[139]	new[139]	_	_
24-6	2695-2698	Apc	event[139]|organization|abstract[141]	new[139]|giv|new[141]	_	_
24-7	2699-2707	function	event[139]|abstract[141]	new[139]|new[141]	_	_
24-8	2708-2709	,	event[139]	new[139]	_	_
24-9	2710-2718	mutation	event[139]|abstract	new[139]|giv	coref	29-6
24-10	2719-2722	and	event[139]	new[139]	_	_
24-11	2723-2731	aberrant	event[139]|abstract[143]	new[139]|new[143]	_	_
24-12	2732-2739	nuclear	event[139]|abstract[143]	new[139]|new[143]	_	_
24-13	2740-2750	expression	event[139]|abstract[143]	new[139]|new[143]	_	_
24-14	2751-2753	of	event[139]|abstract[143]	new[139]|new[143]	_	_
24-15	2754-2763	β-catenin	event[139]|abstract[143]|substance	new[139]|new[143]|new	_	_
24-16	2764-2767	may	_	_	_	_
24-17	2768-2775	disrupt	_	_	_	_
24-18	2776-2779	the	place[146]	giv[146]	coref	29-5[0_146]
24-19	2780-2789	canonical	place[146]	giv[146]	_	_
24-20	2790-2803	Wnt/β-catenin	abstract|place[146]	new|giv[146]	_	_
24-21	2804-2811	pathway	place[146]	giv[146]	_	_
24-22	2812-2813	.	_	_	_	_

#Text=The Stelic Animal Model ( STAM ) demonstrates non-alcoholic steatohepatitis ( NASH ) progression resembling the disease in humans .
25-1	2814-2817	The	abstract[148]	giv[148]	appos	25-6[0_148]
25-2	2818-2824	Stelic	person|abstract[148]	new|giv[148]	_	_
25-3	2825-2831	Animal	abstract[148]	giv[148]	_	_
25-4	2832-2837	Model	abstract[148]	giv[148]	_	_
25-5	2838-2839	(	_	_	_	_
25-6	2840-2844	STAM	abstract	giv	coref	27-1[163_0]
25-7	2845-2846	)	_	_	_	_
25-8	2847-2859	demonstrates	_	_	_	_
25-9	2860-2873	non-alcoholic	abstract[150]	new[150]	appos	25-12[0_150]
25-10	2874-2889	steatohepatitis	abstract[150]	new[150]	_	_
25-11	2890-2891	(	_	_	_	_
25-12	2892-2896	NASH	abstract	giv	coref	26-2
25-13	2897-2898	)	_	_	_	_
25-14	2899-2910	progression	abstract	new	coref	34-25
25-15	2911-2921	resembling	_	_	_	_
25-16	2922-2925	the	abstract[153]	new[153]	coref	34-27[0_153]
25-17	2926-2933	disease	abstract[153]	new[153]	_	_
25-18	2934-2936	in	_	_	_	_
25-19	2937-2943	humans	person	new	coref	29-12[193_0]
25-20	2944-2945	.	_	_	_	_

#Text=Since NASH is evolving as a major cause of non-viral HCC and may account for a large proportion of HCC in developed countries in recent years , HCC arising from NASH is important .
26-1	2946-2951	Since	_	_	_	_
26-2	2952-2956	NASH	substance	giv	coref	26-31
26-3	2957-2959	is	_	_	_	_
26-4	2960-2968	evolving	_	_	_	_
26-5	2969-2971	as	_	_	_	_
26-6	2972-2973	a	_	_	_	_
26-7	2974-2979	major	_	_	_	_
26-8	2980-2985	cause	_	_	_	_
26-9	2986-2988	of	_	_	_	_
26-10	2989-2998	non-viral	object[156]	giv[156]	coref	26-20[0_156]
26-11	2999-3002	HCC	object[156]	giv[156]	_	_
26-12	3003-3006	and	_	_	_	_
26-13	3007-3010	may	_	_	_	_
26-14	3011-3018	account	_	_	_	_
26-15	3019-3022	for	_	_	_	_
26-16	3023-3024	a	quantity[157]	new[157]	_	_
26-17	3025-3030	large	quantity[157]	new[157]	_	_
26-18	3031-3041	proportion	quantity[157]	new[157]	_	_
26-19	3042-3044	of	quantity[157]	new[157]	_	_
26-20	3045-3048	HCC	quantity[157]|object	new[157]|giv	coref	26-28
26-21	3049-3051	in	_	_	_	_
26-22	3052-3061	developed	place[159]	new[159]	_	_
26-23	3062-3071	countries	place[159]	new[159]	_	_
26-24	3072-3074	in	place[159]	new[159]	_	_
26-25	3075-3081	recent	place[159]|time[160]	new[159]|new[160]	_	_
26-26	3082-3087	years	place[159]|time[160]	new[159]|new[160]	_	_
26-27	3088-3089	,	_	_	_	_
26-28	3090-3093	HCC	abstract	giv	coref	28-21
26-29	3094-3101	arising	_	_	_	_
26-30	3102-3106	from	_	_	_	_
26-31	3107-3111	NASH	abstract	giv	coref	28-4
26-32	3112-3114	is	_	_	_	_
26-33	3115-3124	important	_	_	_	_
26-34	3125-3126	.	_	_	_	_

#Text=The STAM model is created by combination of chemical ( a single subcutaneous injection of 200 μg of streptozotocin at two days after birth ) and dietary intervention ( high-fat diet ad libitum four weeks after injection ) in C57BL/6 mice .
27-1	3127-3130	The	abstract[163]	giv[163]	coref	28-1[0_163]
27-2	3131-3135	STAM	abstract[163]	giv[163]	_	_
27-3	3136-3141	model	abstract[163]	giv[163]	_	_
27-4	3142-3144	is	_	_	_	_
27-5	3145-3152	created	_	_	_	_
27-6	3153-3155	by	_	_	_	_
27-7	3156-3167	combination	abstract[164]	new[164]	_	_
27-8	3168-3170	of	abstract[164]	new[164]	_	_
27-9	3171-3179	chemical	abstract[164]|substance	new[164]|giv	_	_
27-10	3180-3181	(	_	_	_	_
27-11	3182-3183	a	event[166]	new[166]	coref	27-37[0_166]
27-12	3184-3190	single	event[166]	new[166]	_	_
27-13	3191-3203	subcutaneous	event[166]	new[166]	_	_
27-14	3204-3213	injection	event[166]	new[166]	_	_
27-15	3214-3216	of	event[166]	new[166]	_	_
27-16	3217-3220	200	event[166]|quantity[167]	new[166]|new[167]	_	_
27-17	3221-3223	μg	event[166]|quantity[167]	new[166]|new[167]	_	_
27-18	3224-3226	of	event[166]|quantity[167]	new[166]|new[167]	_	_
27-19	3227-3241	streptozotocin	event[166]|quantity[167]|substance	new[166]|new[167]|new	_	_
27-20	3242-3244	at	event[166]	new[166]	_	_
27-21	3245-3248	two	event[166]|time[169]	new[166]|new[169]	_	_
27-22	3249-3253	days	event[166]|time[169]	new[166]|new[169]	_	_
27-23	3254-3259	after	event[166]|time[169]	new[166]|new[169]	_	_
27-24	3260-3265	birth	event[166]|time[169]|event	new[166]|new[169]|new	_	_
27-25	3266-3267	)	_	_	_	_
27-26	3268-3271	and	_	_	_	_
27-27	3272-3279	dietary	abstract|event[172]	new|new[172]	_	_
27-28	3280-3292	intervention	event[172]	new[172]	_	_
27-29	3293-3294	(	_	_	_	_
27-30	3295-3303	high-fat	_	_	_	_
27-31	3304-3308	diet	event	giv	_	_
27-32	3309-3311	ad	_	_	_	_
27-33	3312-3319	libitum	_	_	_	_
27-34	3320-3324	four	time[174]	new[174]	_	_
27-35	3325-3330	weeks	time[174]	new[174]	_	_
27-36	3331-3336	after	time[174]	new[174]	_	_
27-37	3337-3346	injection	time[174]|event	new[174]|giv	_	_
27-38	3347-3348	)	_	_	_	_
27-39	3349-3351	in	_	_	_	_
27-40	3352-3359	C57BL/6	animal|animal[177]	new|giv[177]	coref|coref	28-1[179_177]|28-1[179_177]
27-41	3360-3364	mice	animal[177]	giv[177]	_	_
27-42	3365-3366	.	_	_	_	_

#Text=STAM mice manifest NASH at eight weeks , which progresses to fibrosis at 12 weeks , and eventually develops into HCC at a rate of nearly 100 % in males .
28-1	3367-3371	STAM	animal|animal[179]	giv|giv[179]	coref|coref	29-1[188_0]|29-1[188_0]
28-2	3372-3376	mice	animal[179]	giv[179]	_	_
28-3	3377-3385	manifest	_	_	_	_
28-4	3386-3390	NASH	object	giv	coref	31-26
28-5	3391-3393	at	_	_	_	_
28-6	3394-3399	eight	time[181]	new[181]	_	_
28-7	3400-3405	weeks	time[181]	new[181]	_	_
28-8	3406-3407	,	_	_	_	_
28-9	3408-3413	which	_	_	_	_
28-10	3414-3424	progresses	_	_	_	_
28-11	3425-3427	to	_	_	_	_
28-12	3428-3436	fibrosis	object	new	_	_
28-13	3437-3439	at	_	_	_	_
28-14	3440-3442	12	time[183]	new[183]	_	_
28-15	3443-3448	weeks	time[183]	new[183]	_	_
28-16	3449-3450	,	_	_	_	_
28-17	3451-3454	and	_	_	_	_
28-18	3455-3465	eventually	_	_	_	_
28-19	3466-3474	develops	_	_	_	_
28-20	3475-3479	into	_	_	_	_
28-21	3480-3483	HCC	object	giv	coref	36-15
28-22	3484-3486	at	_	_	_	_
28-23	3487-3488	a	abstract[185]	new[185]	_	_
28-24	3489-3493	rate	abstract[185]	new[185]	_	_
28-25	3494-3496	of	abstract[185]	new[185]	_	_
28-26	3497-3503	nearly	abstract[185]|quantity[186]	new[185]|new[186]	_	_
28-27	3504-3507	100	abstract[185]|quantity[186]	new[185]|new[186]	_	_
28-28	3508-3509	%	abstract[185]|quantity[186]	new[185]|new[186]	_	_
28-29	3510-3512	in	abstract[185]|quantity[186]	new[185]|new[186]	_	_
28-30	3513-3518	males	abstract[185]|quantity[186]|person	new[185]|new[186]|new	_	_
28-31	3519-3520	.	_	_	_	_

#Text=The STAM model had pathway mutation rates comparable to those in humans for most pathways with more alterations in receptor tyrosine kinase ( RTK ) signaling and chromatin-modification genes .
29-1	3521-3524	The	abstract[188]	giv[188]	ana	29-10[192_188]
29-2	3525-3529	STAM	abstract[188]	giv[188]	_	_
29-3	3530-3535	model	abstract[188]	giv[188]	_	_
29-4	3536-3539	had	_	_	_	_
29-5	3540-3547	pathway	place|abstract[191]	giv|new[191]	coref|coref	30-13|30-13
29-6	3548-3556	mutation	abstract|abstract[191]	giv|new[191]	coref	30-6
29-7	3557-3562	rates	abstract[191]	new[191]	_	_
29-8	3563-3573	comparable	abstract[191]	new[191]	_	_
29-9	3574-3576	to	_	_	_	_
29-10	3577-3582	those	abstract[192]	giv[192]	coref	30-1[202_192]
29-11	3583-3585	in	abstract[192]	giv[192]	_	_
29-12	3586-3592	humans	abstract[192]|person[193]	giv[192]|giv[193]	_	_
29-13	3593-3596	for	abstract[192]|person[193]	giv[192]|giv[193]	_	_
29-14	3597-3601	most	abstract[192]|person[193]|place[194]	giv[192]|giv[193]|new[194]	coref	37-1[254_194]
29-15	3602-3610	pathways	abstract[192]|person[193]|place[194]	giv[192]|giv[193]|new[194]	_	_
29-16	3611-3615	with	abstract[192]|person[193]|place[194]	giv[192]|giv[193]|new[194]	_	_
29-17	3616-3620	more	abstract[192]|person[193]|place[194]|abstract[195]	giv[192]|giv[193]|new[194]|new[195]	coref	36-29[253_195]
29-18	3621-3632	alterations	abstract[192]|person[193]|place[194]|abstract[195]	giv[192]|giv[193]|new[194]|new[195]	_	_
29-19	3633-3635	in	abstract[192]|person[193]|place[194]|abstract[195]	giv[192]|giv[193]|new[194]|new[195]	_	_
29-20	3636-3644	receptor	abstract[192]|person[193]|place[194]|abstract[195]|substance|abstract[198]	giv[192]|giv[193]|new[194]|new[195]|new|new[198]	appos|appos	29-24[0_198]|29-24[0_198]
29-21	3645-3653	tyrosine	abstract[192]|person[193]|place[194]|abstract[195]|abstract|abstract[198]	giv[192]|giv[193]|new[194]|new[195]|new|new[198]	_	_
29-22	3654-3660	kinase	abstract[192]|person[193]|place[194]|abstract[195]|abstract[198]	giv[192]|giv[193]|new[194]|new[195]|new[198]	_	_
29-23	3661-3662	(	abstract[192]|person[193]|place[194]|abstract[195]	giv[192]|giv[193]|new[194]|new[195]	_	_
29-24	3663-3666	RTK	abstract[192]|person[193]|place[194]|abstract[195]|abstract	giv[192]|giv[193]|new[194]|new[195]|giv	_	_
29-25	3667-3668	)	abstract[192]|person[193]|place[194]|abstract[195]	giv[192]|giv[193]|new[194]|new[195]	_	_
29-26	3669-3678	signaling	abstract[192]|person[193]|place[194]|abstract[195]|abstract	giv[192]|giv[193]|new[194]|new[195]|new	_	_
29-27	3679-3682	and	abstract[192]|person[193]|place[194]|abstract[195]	giv[192]|giv[193]|new[194]|new[195]	_	_
29-28	3683-3705	chromatin-modification	abstract[192]|person[193]|place[194]|abstract[195]|abstract[201]	giv[192]|giv[193]|new[194]|new[195]|giv[201]	_	_
29-29	3706-3711	genes	abstract[192]|person[193]|place[194]|abstract[195]|abstract[201]	giv[192]|giv[193]|new[194]|new[195]|giv[201]	_	_
29-30	3712-3713	.	_	_	_	_

#Text=This model also showed low mutation rate of TP53 but the cell-cycle pathway alteration rate was similar to human tumors .
30-1	3714-3718	This	abstract[202]	giv[202]	coref	31-4[211_202]
30-2	3719-3724	model	abstract[202]	giv[202]	_	_
30-3	3725-3729	also	_	_	_	_
30-4	3730-3736	showed	_	_	_	_
30-5	3737-3740	low	abstract[204]	new[204]	coref	30-11[208_204]
30-6	3741-3749	mutation	abstract|abstract[204]	giv|new[204]	_	_
30-7	3750-3754	rate	abstract[204]	new[204]	_	_
30-8	3755-3757	of	abstract[204]	new[204]	_	_
30-9	3758-3762	TP53	abstract[204]|abstract	new[204]|giv	_	_
30-10	3763-3766	but	_	_	_	_
30-11	3767-3770	the	abstract[208]	giv[208]	_	_
30-12	3771-3781	cell-cycle	abstract[208]	giv[208]	_	_
30-13	3782-3789	pathway	place|abstract[208]	giv|giv[208]	coref	37-6[256_0]
30-14	3790-3800	alteration	abstract|abstract[208]	new|giv[208]	_	_
30-15	3801-3805	rate	abstract[208]	giv[208]	_	_
30-16	3806-3809	was	_	_	_	_
30-17	3810-3817	similar	_	_	_	_
30-18	3818-3820	to	_	_	_	_
30-19	3821-3826	human	abstract[209]	giv[209]	_	_
30-20	3827-3833	tumors	abstract[209]	giv[209]	_	_
30-21	3834-3835	.	_	_	_	_

#Text=The limitation of this model is that the model does not show obesity or insulin resistance , which is the common characteristics of patients with NASH .
31-1	3836-3839	The	abstract[210]	new[210]	_	_
31-2	3840-3850	limitation	abstract[210]	new[210]	_	_
31-3	3851-3853	of	abstract[210]	new[210]	_	_
31-4	3854-3858	this	abstract[210]|abstract[211]	new[210]|giv[211]	coref	31-8[212_211]
31-5	3859-3864	model	abstract[210]|abstract[211]	new[210]|giv[211]	_	_
31-6	3865-3867	is	_	_	_	_
31-7	3868-3872	that	_	_	_	_
31-8	3873-3876	the	abstract[212]	giv[212]	_	_
31-9	3877-3882	model	abstract[212]	giv[212]	_	_
31-10	3883-3887	does	_	_	_	_
31-11	3888-3891	not	_	_	_	_
31-12	3892-3896	show	_	_	_	_
31-13	3897-3904	obesity	abstract	new	_	_
31-14	3905-3907	or	_	_	_	_
31-15	3908-3915	insulin	event|abstract[215]	new|new[215]	_	_
31-16	3916-3926	resistance	abstract[215]	new[215]	_	_
31-17	3927-3928	,	_	_	_	_
31-18	3929-3934	which	_	_	_	_
31-19	3935-3937	is	_	_	_	_
31-20	3938-3941	the	abstract[216]	new[216]	_	_
31-21	3942-3948	common	abstract[216]	new[216]	_	_
31-22	3949-3964	characteristics	abstract[216]	new[216]	_	_
31-23	3965-3967	of	abstract[216]	new[216]	_	_
31-24	3968-3976	patients	abstract[216]|person[217]	new[216]|new[217]	_	_
31-25	3977-3981	with	abstract[216]|person[217]	new[216]|new[217]	_	_
31-26	3982-3986	NASH	abstract[216]|person[217]|abstract	new[216]|new[217]|giv	_	_
31-27	3987-3988	.	_	_	_	_

#Text=2.2 .
32-1	3989-3992	2.2	abstract	new	_	_
32-2	3993-3994	.	_	_	_	_

#Text=Genetically Engineered Mouse Models
33-1	3995-4006	Genetically	abstract[220]	new[220]	coref	34-7[0_220]
33-2	4007-4017	Engineered	abstract[220]	new[220]	_	_
33-3	4018-4023	Mouse	abstract[220]	new[220]	_	_
33-4	4024-4030	Models	abstract[220]	new[220]	_	_

#Text=Genetically engineered mouse ( GEM ) models recapitulate the multistep process of hepatocarcinogenesis with multiple genetic and epigenetic changes occurring along each stage of progression toward cancer formation .
34-1	4031-4042	Genetically	animal[221]	giv[221]	_	_
34-2	4043-4053	engineered	animal[221]	giv[221]	_	_
34-3	4054-4059	mouse	animal[221]	giv[221]	_	_
34-4	4060-4061	(	_	_	_	_
34-5	4062-4065	GEM	substance	giv	_	_
34-6	4066-4067	)	_	_	_	_
34-7	4068-4074	models	abstract	giv	_	_
34-8	4075-4087	recapitulate	_	_	_	_
34-9	4088-4091	the	abstract[224]	new[224]	_	_
34-10	4092-4101	multistep	abstract[224]	new[224]	_	_
34-11	4102-4109	process	abstract[224]	new[224]	_	_
34-12	4110-4112	of	abstract[224]	new[224]	_	_
34-13	4113-4133	hepatocarcinogenesis	abstract[224]|abstract[225]	new[224]|giv[225]	_	_
34-14	4134-4138	with	abstract[224]|abstract[225]	new[224]|giv[225]	_	_
34-15	4139-4147	multiple	abstract[224]|abstract[225]|abstract[226]	new[224]|giv[225]|new[226]	_	_
34-16	4148-4155	genetic	abstract[224]|abstract[225]|abstract[226]	new[224]|giv[225]|new[226]	_	_
34-17	4156-4159	and	abstract[224]|abstract[225]	new[224]|giv[225]	_	_
34-18	4160-4170	epigenetic	abstract[224]|abstract[225]|abstract|abstract[228]	new[224]|giv[225]|new|giv[228]	ana|ana	35-1[0_228]|35-1[0_228]
34-19	4171-4178	changes	abstract[224]|abstract[225]|abstract[228]	new[224]|giv[225]|giv[228]	_	_
34-20	4179-4188	occurring	_	_	_	_
34-21	4189-4194	along	_	_	_	_
34-22	4195-4199	each	event[229]	new[229]	_	_
34-23	4200-4205	stage	event[229]	new[229]	_	_
34-24	4206-4208	of	event[229]	new[229]	_	_
34-25	4209-4220	progression	event[229]|event	new[229]|giv	_	_
34-26	4221-4227	toward	event[229]	new[229]	_	_
34-27	4228-4234	cancer	event[229]|abstract|abstract[232]	new[229]|giv|new[232]	_	_
34-28	4235-4244	formation	event[229]|abstract[232]	new[229]|new[232]	_	_
34-29	4245-4246	.	_	_	_	_

#Text=They are highly useful for assessing the impacts of a driver oncogene alone or in combination with other driver oncogenes or tumor suppressors .
35-1	4247-4251	They	abstract	giv	_	_
35-2	4252-4255	are	_	_	_	_
35-3	4256-4262	highly	_	_	_	_
35-4	4263-4269	useful	_	_	_	_
35-5	4270-4273	for	_	_	_	_
35-6	4274-4283	assessing	_	_	_	_
35-7	4284-4287	the	abstract[234]	new[234]	_	_
35-8	4288-4295	impacts	abstract[234]	new[234]	_	_
35-9	4296-4298	of	abstract[234]	new[234]	_	_
35-10	4299-4300	a	abstract[234]|abstract[236]	new[234]|new[236]	_	_
35-11	4301-4307	driver	abstract[234]|person|abstract[236]	new[234]|new|new[236]	coref	35-19
35-12	4308-4316	oncogene	abstract[234]|abstract[236]	new[234]|new[236]	_	_
35-13	4317-4322	alone	abstract[234]|abstract[236]	new[234]|new[236]	_	_
35-14	4323-4325	or	_	_	_	_
35-15	4326-4328	in	_	_	_	_
35-16	4329-4340	combination	_	_	_	_
35-17	4341-4345	with	_	_	_	_
35-18	4346-4351	other	abstract[238]	new[238]	_	_
35-19	4352-4358	driver	person|abstract[238]	giv|new[238]	_	_
35-20	4359-4368	oncogenes	abstract[238]	new[238]	_	_
35-21	4369-4371	or	_	_	_	_
35-22	4372-4377	tumor	abstract|object[240]	giv|new[240]	_	_
35-23	4378-4389	suppressors	object[240]	new[240]	_	_
35-24	4390-4391	.	_	_	_	_

#Text=Recently , the Cancer Genome Atlas ( TCGA ) characterized the genomic landscape of HCC using large-scale multi-platform analysis of HCC , including evaluation of somatic mutations and copy number alterations .
36-1	4392-4400	Recently	_	_	_	_
36-2	4401-4402	,	_	_	_	_
36-3	4403-4406	the	person[243]	new[243]	_	_
36-4	4407-4413	Cancer	abstract|person[243]	giv|new[243]	_	_
36-5	4414-4420	Genome	abstract|person[243]	new|new[243]	_	_
36-6	4421-4426	Atlas	person[243]	new[243]	_	_
36-7	4427-4428	(	_	_	_	_
36-8	4429-4433	TCGA	abstract	new	_	_
36-9	4434-4435	)	_	_	_	_
36-10	4436-4449	characterized	_	_	_	_
36-11	4450-4453	the	abstract[245]	new[245]	_	_
36-12	4454-4461	genomic	abstract[245]	new[245]	_	_
36-13	4462-4471	landscape	abstract[245]	new[245]	_	_
36-14	4472-4474	of	abstract[245]	new[245]	_	_
36-15	4475-4478	HCC	abstract[245]|organization	new[245]|giv	coref	36-21
36-16	4479-4484	using	_	_	_	_
36-17	4485-4496	large-scale	abstract[247]	new[247]	_	_
36-18	4497-4511	multi-platform	abstract[247]	new[247]	_	_
36-19	4512-4520	analysis	abstract[247]	new[247]	_	_
36-20	4521-4523	of	abstract[247]	new[247]	_	_
36-21	4524-4527	HCC	abstract[247]|object	new[247]|giv	_	_
36-22	4528-4529	,	abstract[247]	new[247]	_	_
36-23	4530-4539	including	abstract[247]	new[247]	_	_
36-24	4540-4550	evaluation	abstract[247]|abstract[249]	new[247]|new[249]	_	_
36-25	4551-4553	of	abstract[247]|abstract[249]	new[247]|new[249]	_	_
36-26	4554-4561	somatic	abstract[247]|abstract[249]|abstract[250]	new[247]|new[249]|giv[250]	_	_
36-27	4562-4571	mutations	abstract[247]|abstract[249]|abstract[250]	new[247]|new[249]|giv[250]	_	_
36-28	4572-4575	and	abstract[247]|abstract[249]|abstract[250]	new[247]|new[249]|giv[250]	_	_
36-29	4576-4580	copy	abstract[247]|abstract[249]|abstract[250]|object|abstract[253]	new[247]|new[249]|giv[250]|new|giv[253]	_	_
36-30	4581-4587	number	abstract[247]|abstract[249]|abstract[250]|place|abstract[253]	new[247]|new[249]|giv[250]|new|giv[253]	_	_
36-31	4588-4599	alterations	abstract[247]|abstract[249]|abstract[250]|abstract[253]	new[247]|new[249]|giv[250]|giv[253]	_	_
36-32	4600-4601	.	_	_	_	_

#Text=Commonly altered pathways such as cell cycle pathway , RTK/RAS/PI3K , and WNT pathways were also identified and therefore , data generated from GEMs would be useful in developing novel therapies and be tested in the preclinical setting if they recapitulate human HCCs .
37-1	4602-4610	Commonly	place[254]	giv[254]	_	_
37-2	4611-4618	altered	place[254]	giv[254]	_	_
37-3	4619-4627	pathways	place[254]	giv[254]	_	_
37-4	4628-4632	such	place[254]	giv[254]	_	_
37-5	4633-4635	as	place[254]	giv[254]	_	_
37-6	4636-4640	cell	place[254]|place[256]	giv[254]|giv[256]	_	_
37-7	4641-4646	cycle	place[254]|abstract|place[256]	giv[254]|new|giv[256]	_	_
37-8	4647-4654	pathway	place[254]|place[256]	giv[254]|giv[256]	_	_
37-9	4655-4656	,	place[254]	giv[254]	_	_
37-10	4657-4669	RTK/RAS/PI3K	place[254]|abstract	giv[254]|new	_	_
37-11	4670-4671	,	place[254]	giv[254]	_	_
37-12	4672-4675	and	place[254]	giv[254]	_	_
37-13	4676-4679	WNT	place[254]|abstract	giv[254]|new	_	_
37-14	4680-4688	pathways	place[254]	giv[254]	_	_
37-15	4689-4693	were	_	_	_	_
37-16	4694-4698	also	_	_	_	_
37-17	4699-4709	identified	_	_	_	_
37-18	4710-4713	and	_	_	_	_
37-19	4714-4723	therefore	_	_	_	_
37-20	4724-4725	,	_	_	_	_
37-21	4726-4730	data	abstract	new	_	_
37-22	4731-4740	generated	_	_	_	_
37-23	4741-4745	from	_	_	_	_
37-24	4746-4750	GEMs	object	new	ana	37-40
37-25	4751-4756	would	_	_	_	_
37-26	4757-4759	be	_	_	_	_
37-27	4760-4766	useful	_	_	_	_
37-28	4767-4769	in	_	_	_	_
37-29	4770-4780	developing	_	_	_	_
37-30	4781-4786	novel	abstract[261]	new[261]	_	_
37-31	4787-4796	therapies	abstract[261]	new[261]	_	_
37-32	4797-4800	and	_	_	_	_
37-33	4801-4803	be	_	_	_	_
37-34	4804-4810	tested	_	_	_	_
37-35	4811-4813	in	_	_	_	_
37-36	4814-4817	the	abstract[262]	new[262]	_	_
37-37	4818-4829	preclinical	abstract[262]	new[262]	_	_
37-38	4830-4837	setting	abstract[262]	new[262]	_	_
37-39	4838-4840	if	_	_	_	_
37-40	4841-4845	they	object	giv	_	_
37-41	4846-4858	recapitulate	_	_	_	_
37-42	4859-4864	human	object[264]	giv[264]	_	_
37-43	4865-4869	HCCs	object[264]	giv[264]	_	_
37-44	4870-4871	.	_	_	_	_
